Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients
- Simsek, M.
- Meijer, B.
- Ramsoekh, D.
- Bouma, G.
- Wouden, E.J. van der
- Hartog, B. den
- Vries, A.C.M. de
- Hoentjen, F.
- Dijkstra, G.
- Boer, Sybrand Y. de
- Jansen, J.M
- Meulen, A.E. van der
- Beukers, R.
- Brink, M.A.
- Steinhauser, T.
- Oldenburg, B.
- Gilissen, L.P.
- Naber, T.H.
- Verhagen, M.A.
- Boer, N.K. de
- Mulder, C.J.
DOIAbstract
Item does not contain fulltextNodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD).(1) It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown.(2) The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course
Add to ORKG